The practice
KEP Advisory works with lean and virtual biopharmaceutical companies at the point where early science has to become a clinical program. The work is hands-on: leading the company, running the outsourced team, and making the regulatory, manufacturing, and financing decisions that move a molecule into patients.
Areas of work
-
Executive leadership
Chief executive and senior operating roles, from board governance and corporate strategy to day-to-day program management.
-
Clinical and regulatory strategy
Development planning, FDA engagement, expedited-program designations, and trial design built around the current standard of care.
-
CMC and outsourcing oversight
Selecting and managing CDMOs, CROs, and specialist consultants across GMP biologics manufacturing, GLP toxicology, and clinical execution.
-
Capital formation
Financing strategy, investor materials, grant funding, and ongoing board and shareholder communication.
-
Corporate development
Licensing, acquisitions, intellectual-property strategy, and technical due diligence.
-
Cross-border operations
Building and running companies across the United States and Australia, including subsidiary formation and R&D incentive programs.
Principal
Kent E. Pryor
Ph.D., M.B.A., Principal
Kent Pryor has spent more than twenty-five years in biopharmaceutical research and development, first as a medicinal chemist and later as an operator and chief executive. He led 3K3A-APC, an engineered variant of activated protein C, from GLP toxicology and GMP manufacturing through a multicenter Phase 2 trial and FDA Fast Track designation, and has raised equity and grant funding to support clinical programs in the United States and Australia.
He holds a Ph.D. in organic chemistry from MIT, an M.B.A. from the Rady School of Management at UC San Diego, and a B.A. in chemistry from Rice University.